Evidence Hub

Empagliflozin Treatment for Patients with Heart Failure with Preserved Ejection Fraction-A Systematic Review

Cardiology: Open Access, 2023

Abstract

Objective: The goal of this systematic review is to determine the effectiveness of empagliflozin in managing patients with heart failure with preserved ejection fraction (HFpEF) as compared with a placebo. Methods: Web of Science, Cochrane, PubMed, and Scopus databases were searched for articles from 2000 to November 2022. Reference lists of articles were manually screened. Trials that recruited patients with HFpEF and reported the effects of empagliflozin were included. Endnote X9 software was used for study screening process. Results: 14 papers out of 1235 found were selected for full-text reviews. The systematic review included nine papers that were all randomized controlled trials. According to the findings of individual trials, empagliflozin is more effective and has a statistically insignificant safety advantage over a placebo. Conclusion: Empagliflozin treatment for HFpEF patients appears to be both safe and efficient when compared to a placebo, according to data of moderate quality

How strong is the evidence?

Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free